Literature DB >> 8102101

Enhancing effect of natural killer cell stimulatory factor (NKSF/interleukin-12) on cell-mediated cytotoxicity against tumor-derived and virus-infected cells.

J Chehimi1, N M Valiante, A D'Andrea, M Rengaraju, Z Rosado, M Kobayashi, B Perussia, S F Wolf, S E Starr, G Trinchieri.   

Abstract

Natural killer cell stimulatory factor (NKSF) or interleukin-12 (IL-12) is a heterodimeric cytokine with pleiomorphic effects on T and NK cells, including induction of lymphokine production, mitogenesis, and enhancement of spontaneous cytotoxic activity. Similarly to IL-2, NKSF/IL-12 enhances NK cell-mediated cytotoxicity within a few hours and independently from induced proliferation. This effect is independent from other induced cytokines, because it is not prevented by antibodies neutralizing interferon (IFN)-alpha, IFN-beta, IFN-gamma, IL-2 or tumor necrosis factor (TNF)-alpha and, unlike the induction of IFN-gamma production by peripheral blood lymphocytes, it does not require HLA class II-positive accessory cells. Enhanced cytotoxicity is accompanied by morphologic changes in NK cells, including a significant increase in the number of cytoplasmic granules. In addition to the previously described ability to enhance the cytotoxic activity of NK cells against tumor-derived target cells, NKSF/IL-12 is also a potent stimulator of cytotoxicity against virus-infected cells, either fibroblasts acutely infected with herpes viruses or T cell lines chronically infected with human immunodeficiency virus-1. NK cell-mediated antibody-dependent cytotoxicity or anti-CD16 antibody-redirected lysis is not significantly enhanced by NKSF/IL-12. However, the ability of resting peripheral blood T cells to mediate anti-CD3 antibody-redirected lysis is enhanced by 18-h incubation with NKSF/IL-12, indicating that this lymphokine can modulate the cytotoxic capability of both NK and T cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8102101     DOI: 10.1002/eji.1830230814

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  31 in total

1.  Primary immune responses by cord blood CD4(+) T cells and NK cells inhibit Epstein-Barr virus B-cell transformation in vitro.

Authors:  A Douglas Wilson; Andrew J Morgan
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

2.  The in vitro effects of interleukin-12 upon tumor-infiltrating lymphocytes derived from renal cell carcinoma.

Authors:  G G Steger; M F Gnant; M P Djavanmard; R M Mader; R Jakesz; W Pierce; J B deKernion; R Figlin; A Belldegrun
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

3.  TL1A selectively enhances IL-12/IL-18-induced NK cell cytotoxicity against NK-resistant tumor targets.

Authors:  Stephanie C Heidemann; Valerie Chavez; Carol J Landers; Torsten Kucharzik; John L Prehn; Stephan R Targan
Journal:  J Clin Immunol       Date:  2010-03-27       Impact factor: 8.317

4.  IL-12 in conjunction with dendritic cells enhances antiviral CD8+ CTL responses in vitro.

Authors:  N Bhardwaj; R A Seder; A Reddy; M V Feldman
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

5.  Interleukin-12 exhibits potent antiviral activity in experimental herpesvirus infections.

Authors:  J A Carr; J Rogerson; M J Mulqueen; N A Roberts; R F Booth
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

6.  Interleukin-12 promotes activation of effector cells that induce a severe destructive granulomatous form of murine experimental autoimmune thyroiditis.

Authors:  H Braley-Mullen; G C Sharp; H Tang; K Chen; M Kyriakos; J T Bickel
Journal:  Am J Pathol       Date:  1998-05       Impact factor: 4.307

7.  Intrathecal production of interleukin-12 and gamma interferon in patients with bacterial meningitis.

Authors:  R F Kornelisse; C E Hack; H F Savelkoul; T C van der Pouw Kraan; W C Hop; G van Mierlo; M H Suur; H J Neijens; R de Groot
Journal:  Infect Immun       Date:  1997-03       Impact factor: 3.441

Review 8.  Immunobiology of interleukin-12.

Authors:  G Trinchieri
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

9.  Interleukin-15 enhances cytotoxicity, receptor expression, and expansion of neonatal natural killer cells in long-term culture.

Authors:  Sunwoong S Choi; Vaninder S Chhabra; Quoc H Nguyen; Bonnie J Ank; E Richard Stiehm; Robert L Roberts
Journal:  Clin Diagn Lab Immunol       Date:  2004-09

10.  Disruption of MAP kinase activation and nuclear factor binding to the IL-12 p40 promoter in HIV-infected myeloid cells.

Authors:  K A Chambers; R J Parks; J B Angel
Journal:  Clin Exp Immunol       Date:  2004-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.